A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal

Primary tabs

field_vote: 
Average: 10 (1 vote)
Number of included patients: 
Publication type: 
Therapeutic Substance(s): 
References: 

A
prospective observational clinical study involving an alternative cancer
treatment, psorinum therapy, in treating stomach, gallbladder,
pancreas, and liver cancers.

 

 
Sub-category:


Other: developmental therapeutics: immunotherapy

 
Category:

Developmental Therapeutics: Immunotherapy

 
Meeting:


2009 ASCO Annual Meeting

 
Session Type and
Session Title:

General Poster Session, Developmental Therapeutics: Immunotherapy

 
Abstract No:

3050

 
Citation:

J Clin Oncol 27:15s, 2009 (suppl; abstr 3050)

 
Author(s):

A. Chatterjee, S. Bhattacharya,
A. K. Chatterjee, J. Biswas, B. Mukhopadhyay; Critical Cancer Management
Research Centre, Kolkata, India; Chittaranjan National Cancer
Institute, Kolkata, India; National Institute of Technology, Durgapur,
India

Abstract:
Background: The prospective
observational clinical study was conducted to know the efficacy of an
alternative cancer treatment, 'psorinum therapy,' in treating liver,
gall bladder, pancreatic, and stomach cancers. The primary outcome
measures of the study were (1) to assess the radiological tumor
response; (2) to assess how many participants survived at least 1 year, 2
years, 3 years, 4 years, and finally, 5 years after the beginning of
the study. The secondary outcome measure of the study was to assess the
side effects of the investigational anti-cancer drug (psorinum) if any. Methods:
The drug psorinum (an alcoholic extract of scabies, scrub, slough, and
pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a
single dose in empty stomach per day and ongoing to all the
participants along with allopathic and homeopathic supportive cares.
Results:
158 histopathology or cytopathology proved participants (42 of stomach,
40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were
included in the final analysis at the end of the study. According to the
AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II,
39 (24.68%) of them diagnosed at late stage II or early stage III and
112 (70.87%) of them diagnosed at late stage III or stage IV. According
to the RECIST criteria, complete tumor response occurred in 28 (17.72%)
cases and partial tumor response occurred in 56 (35.44%) cases. 126
(79.75%) of them survived at least 1 year, 99 (62.66%) of them survived
at least 2 years, 87 (55.06%) of them survived at least 3 years, 76
(48.10%) of them survived at least 4 years, and 62 (39.24%) of them
survived at least 5 years. These participants did not receive any other
conventional or investigational cancer treatments. The participants
report no side effects from the drug psorinum.
Conclusions:
Psorinum therapy is effective in treating stomach, gallbladder,
pancreas, and liver cancers. Double-blinded randomized controlled
clinical trial should be done for further investigation of this
alternative cancer treatment.